Daily Stock Analysis, BLRX, BioLine RX Ltd, priceseries

BioLine RX Ltd. Daily Stock Analysis
Stock Information
Open
2.73
Close
2.68
High
2.77
Low
2.66
Previous Close
2.70
Daily Price Gain
-0.02
YTD High
12.98
YTD High Date
Feb 4, 2019
YTD Low
2.32
YTD Low Date
Sep 3, 2019
YTD Price Change
-4.82
YTD Gain
-64.27%
52 Week High
22.05
52 Week High Date
Oct 18, 2018
52 Week Low
2.32
52 Week Low Date
Sep 3, 2019
52 Week Price Change
-18.62
52 Week Gain
-87.42%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 25. 2017
14.10
Feb 23. 2017
18.17
20 Trading Days
28.85%
Link
LONG
Jul 13. 2017
13.05
Aug 16. 2017
16.99
24 Trading Days
30.17%
Link
LONG
Oct 2. 2017
17.25
Oct 12. 2017
18.37
8 Trading Days
6.48%
Link
LONG
Nov 24. 2017
15.60
Dec 6. 2017
16.42
8 Trading Days
5.26%
Link
LONG
Sep 19. 2018
13.95
Oct 9. 2018
18.45
14 Trading Days
32.26%
Link
LONG
Jan 7. 2019
7.65
Jan 18. 2019
8.16
9 Trading Days
6.61%
Link
LONG
Jun 19. 2019
5.25
Jun 24. 2019
5.51
3 Trading Days
5.00%
Link
Company Information
Stock Symbol
BLRX
Exchange
NasdaqCM
Company URL
http://www.biolinerx.com
Company Phone
972-2-548-9100
CEO
Philip Adam Serlin
Headquarters
-
Business Address
2 HAMA-AYAN STREET, MODI-IN TECHNOLOGY PARK, MODI-IN, ISRAEL 7177871
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001498403
About

BioLineRx Ltd. is a clinical-stage biopharmaceutical company, which includes indentifying, in-licensing, and developing therapeutic candidates. Its in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel, and develops them through pre-clinical and clinical stages, and then partners with pharmaceutical companies clinical development and commercialization. The company was founded in April 2003 and is headquartered in Modi'in, Israel.

Description

BioLineRx Ltd., a clinical stage biopharmaceutical development company, is engaged in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company's development pipeline consists of clinical-stage therapeutic candidates, including BL-1040, a resorbable polymer solution being developed to reduce or prevent the ventricular remodeling; BL-8040, a peptide for the treatment of acute myeloid leukemia, stem cell mobilization, and other hematological indications; BL-7010, a polymer for the treatment of celiac disease; BL-5010, which is being developed as a medical device for the non-surgical removal of benign skin lesions; BL-7040, an oligonucleotide for the treatment of inflammatory bowel disease; and BL-8020, an orally available treatment for the Hepatitis C virus and other viral indications. It also has three therapeutic candidates in the preclinical stages of development, such as BL-8030 for the treatment of Hepatitis C; BL-9010 to treat severe allergies/asthma; and BL-9020 for the treatment of type 1 diabetes. BioLineRx Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.